The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition ...

JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green ...

Limited launch expected for JenaValve's Trilogy System ...

JenaValve's Trilogy System, FDA-approved for severe AR, offers secure anchoring without calcium. It is a breakthrough for ...

JenaValve announced today that it has received FDA premarket approval (PMA) for its Trilogy transcatheter heart valve system.

PARIS -- The early commercial experience with transcatheter aortic valve replacement (TAVR or TAVI) for severe aortic regurgitation appeared promising, though device size issues and conduction ...

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket ...

A bicuspid aortic valve may present few problems throughout your life. But you’ll still need to live a heart-healthy lifestyle and monitor your cardiovascular system to prevent complications. The ...

BACKGROUND: Aortic valve calcification increases leaflet stiffness and contributes to the development of calcific aortic valve disease. The molecular and cellular mechanisms underlying calcification ...

Your aortic valve is part of your heart, a strong muscle that pumps blood through your body. The aortic valve controls the blood flowing out from the heart. It opens every time your heart contracts, ...

Bicuspid aortic valve (BAV) is a congenital heart condition. It occurs when the aortic valve has two cusps instead of the three. BAV can lead to serious complications. Several treatment options can ...

Aortic valve insufficiency is a form of valvular heart disease. It occurs when the aortic valve does not function properly. This may cause the heart to work harder and can lead to heart failure.